Artículos por temáticas

Biomarker treatment effects in two phase 3 trials of gantenerumab

Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, Delmar P, Scelsi MA, Gobbi S, Silvestri E, Barakovic M, Napolitano A, Galli C, Abaei M, Blennow K, Barkhof F.

Alzheimers Dement. 2025 Feb;21(2):e14414. doi: 10.1002/alz.14414. Epub 2025 Jan 30.

Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable

Farrar G, Weber CJ, Rabinovici GD.

J Prev Alzheimers Dis. 2025 Jan;12(1):100008. doi: 10.1016/j.tjpad.2024.100008. Epub 2025 Jan 1.

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, Zhang H, Jerecic J, Honig LS, Salloway S, Sperling R, Trame MN, Dodds MG, Johnson K.

J Prev Alzheimers Dis. 2025 Jan;12(1):100005. doi: 10.1016/j.tjpad.2024.100005. Epub 2025 Jan 1.

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease

Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, León T, Scheltens P.

Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7.

Beta-site APP-cleaving Enzyme-1 Inhibitory Role of Natural Flavonoids in the Treatment of Alzheimer's Disease

Singh S, Kushwaha V, Sisodia S, Kumar S, Sahu KK.

Cent Nerv Syst Agents Med Chem. 2025;25(1):39-48. doi: 10.2174/0118715249315049240710063455.

Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial

Ayasse ND, Stewart WF, Lipton RB, Gomez-Ulloa D, Runken MC.

Curr Alzheimer Res. 2025;21(5):353-365. doi: 10.2174/0115672050316936240905064215.

Playing Around the Coumarin Core in the Discovery of Multimodal Compounds Directed at Alzheimer's-Related Targets: A Recent Literature Overview

Rullo M, La Spada G, Stefanachi A, Macchia E, Pisani L, Leonetti F.

Molecules. 2025 Feb 14;30(4):891. doi: 10.3390/molecules30040891.

Deoxyvasicinone hybrids in the management of Alzheimer's disease: Recent advances on manmade derivatives, pharmacological activities, and structure-activity relationship

Gaur A, Singh YP, Sharma R, Bainsal N.

Arch Pharm (Weinheim). 2025 Jan;358(1):e2400742. doi: 10.1002/ardp.202400742.

Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer's disease in type 2 diabetes

Ramakrishan P, Rajangam J, Mahinoor SS, Bisht S, Mekala S, Upadhyay DK, Solomon VR, Sabarees G, Pelluri R.

Metab Brain Dis. 2025 Feb 26;40(3):132. doi: 10.1007/s11011-025-01555-4.

The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect

Andrews D, Ducharme S, Chertkow H, Sormani MP, Collins DL; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2025 Jan;21(1):e14467. doi: 10.1002/alz.14467.

The neuroprotective role of volatile oils: insights into chemical profiles, characteristics, neurochemical mechanisms, and preclinical studies in Alzheimer's disease

Suryawanshi M, Gujarathi P, Prajapati B, Vinchurkar K, Gujarathi P.

Inflammopharmacology. 2025 Feb;33(2):627-667. doi: 10.1007/s10787-024-01626-5. Epub 2025 Jan 22.

Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials

Weiner MW, Kanoria S, Miller MJ, Aisen PS, Beckett LA, Conti C, Diaz A, Flenniken D, Green RC, Harvey DJ, Jack CR Jr, Jagust W, Lee EB, Morris JC, Nho K, Nosheny R, Okonkwo OC, Perrin RJ, Petersen RC,

Alzheimers Dement. 2025 Jan;21(1):e14321. doi: 10.1002/alz.14321. Epub 2024 Dec 22.

Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity

Zhang Y, Chen J, Li Y, Jiao B, Luo S.

Ageing Res Rev. 2025 Jan;103:102595. doi: 10.1016/j.arr.2024.102595. Epub 2024 Nov 22.

Molecular Therapeutics in Development to Treat Alzheimer's Disease

Tartaglia MC, Ingelsson M.

Mol Diagn Ther. 2025 Jan;29(1):9-24. doi: 10.1007/s40291-024-00738-6. Epub 2024 Sep 24.

"Current and emerging drug therapies in Alzheimer's disease: A pathophysiological Perspective"

Aparajita A, Jain U, Srivastava P.

Neuroscience. 2025 Jan 26;565:499-518. doi: 10.1016/j.neuroscience.2024.11.078. Epub 2024 Dec 9.